Source:http://linkedlifedata.com/resource/pubmed/id/15800667
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2005-5-24
|
| pubmed:abstractText |
A total of 24 patients (median age 58; range, 27-71 years) with chronic myeloid leukemia (CML) in first chronic (CP1) (n=14), second chronic (n=4), or accelerated phase (n=6) who were not candidates for conventional hematopoietic cell transplantation (HCT), received nonmyeloablative HCT from HLA-matched siblings a median of 28.5 (range, 11-271) months after diagnosis. They were conditioned with 2 Gy total body irradiation (TBI) alone (n=8) or combined with fludarabine, 90 mg/m(2) (n=16). Postgrafting immunosuppression included cyclosporine and mycophenolate mofetil. All patients initially engrafted. However, 4 of 8 patients not given fludarabine experienced nonfatal rejection while all others had sustained engraftment. With a median follow-up of 36 (range, 4-49) months, 13 of 24 patients (54%) were alive and in complete remission. There were five (21%) deaths from nonrelapse mortality, one (4%) during the first 100 days after transplant. The proportions of grade II, III, and IV acute GVHD were 38, 4, and 8%, respectively. The 2-year estimate of chronic GVHD was 32%. The 2-year survival estimates for patients in CP1 (n=14) and beyond CP1 (n=10) were 70 and 56%, respectively. This study shows encouraging remission rates for patients with CML not eligible for conventional allografting.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0887-6924
|
| pubmed:author |
pubmed-author:AguraEE,
pubmed-author:Al-AliH KHK,
pubmed-author:BlumeK GKG,
pubmed-author:BruniDD,
pubmed-author:ChaunceyT RTR,
pubmed-author:EpnerE MEM,
pubmed-author:GooleyTT,
pubmed-author:HegenbartUU,
pubmed-author:KerbauyF RFR,
pubmed-author:MaloneyD GDG,
pubmed-author:NiederwieserDD,
pubmed-author:RadichJ PJP,
pubmed-author:SandmaierB MBM,
pubmed-author:ShizuruJJ,
pubmed-author:StorbRR
|
| pubmed:issnType |
Print
|
| pubmed:volume |
19
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
990-7
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15800667-Adult,
pubmed-meshheading:15800667-Aged,
pubmed-meshheading:15800667-Antineoplastic Agents,
pubmed-meshheading:15800667-Female,
pubmed-meshheading:15800667-Graft vs Host Disease,
pubmed-meshheading:15800667-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:15800667-Histocompatibility Testing,
pubmed-meshheading:15800667-Humans,
pubmed-meshheading:15800667-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:15800667-Male,
pubmed-meshheading:15800667-Middle Aged,
pubmed-meshheading:15800667-Radiation Dosage,
pubmed-meshheading:15800667-Siblings,
pubmed-meshheading:15800667-Tissue Donors,
pubmed-meshheading:15800667-Transplantation, Homologous,
pubmed-meshheading:15800667-Transplantation Chimera,
pubmed-meshheading:15800667-Transplantation Conditioning,
pubmed-meshheading:15800667-Treatment Outcome,
pubmed-meshheading:15800667-Vidarabine,
pubmed-meshheading:15800667-Whole-Body Irradiation
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML.
|
| pubmed:affiliation |
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Research Support, N.I.H., Extramural
|